Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Posts Increased Q1 Revenues

NEW YORK (GenomeWeb) – Interleukin Genetics reported a more than twofold increase in first quarter revenues, which contributed to a 17 percent decline in its net loss for the period.

"Our focus … over the past year has been on developing a commercial plan that will drive market adoption of PerioPredict, our genetic test that identifies individuals with an increased risk for severe and progressive periodontitis," Interleukin CEO Mark Carbeau said in a statement. "We also continue to explore other genetic testing applications, such as in cardiovascular disease, where the utility of our test panels may help physicians better manage patients and drive improved outcomes."

For the three-month period ended March 31, Interleukin's revenues climbed to $961,918 from $403,212 a year earlier. The change, Interleukin said, was primarily due to a contracted research program, partially offset by a decrease in weight management genetic test kits returned for processing through a promotion product bundle program with a third party. 

Interleukin's Q1 net loss dipped to $1.5 million, or $.01 per share, from $1.8 million, or $.01 per share, in the year-ago quarter.

R&D spending in the quarter jumped to $480,000 from $183,000, largely reflecting the transition of former CEO Kenneth Kornman to the position of president and CSO. Previously, expenses generated by Kornman were recorded as SG&A costs. 

Interleukin's Q1 SG&A expenses fell to $1.3 million from $1.6 million, a decrease tied to lower compensation costs, CEO recruiting expenses in 2015, and the change in the recording of Kornman's expenses.

At the end of Q1, Interleukin had cash and cash equivalents totaling $2.9 million, which are expected to fund the firm's operations into the second half of the year.

During midday trading on the Over-the-Counter Markets, shares of Waltham, Massachusetts-based Interleukin were up 5 percent at $.21.